Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Incyte 1.674, Vertex Pharmaceuticals 3.334.
Incyte vs Vertex Pharmaceuticals: Revenue Comparison
Incyte (INCY) and Vertex Pharmaceuticals (VRTX) are peers in Healthcare. Incyte reported revenue of $1.7B as of Q2 2026, compared with $3.3B for Vertex Pharmaceuticals. Vertex Pharmaceuticals leads on revenue.
Incyte's gross margin is 93.7% versus 85.3% for Vertex Pharmaceuticals. Incyte's net margin is 35.0% versus 33.0% for Vertex Pharmaceuticals.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Incyte, Vertex Pharmaceuticals.| Metric | Incyte | Vertex Pharmaceuticals |
|---|---|---|
| Market Cap | - | - |
| Revenue | $1.67B | $3.33B |
| Cost of Revenue | $105.00M | $489.00M |
| Gross Profit | $1.57B | $2.85B |
| Operating Income | $698.00M | $1.25B |
| Net Income | $586.00M | $1.10B |
| R&D Expense | $517.00M | $994.00M |
| Earnings Per Share | $2.81 | $4.31 |
| Gross Margin | 93.7% | 85.3% |
| Operating Margin | 41.7% | 37.4% |
| Net Profit Margin | 35.0% | 33.0% |
| Free Cash Flow | $495.00M | $1.01B |
| Cumulative Free Cash Flow | $3.86B | $17.24B |
| Operating Cash Flow | $508.00M | $1.13B |
| Cash & Equivalents | $3.98B | $6.14B |